Eli Lilly to buy cancer-focused Point Biopharma for $1.4 billion
© Reuters. FILE PHOTO: An Eli Lilly and Company pharmaceutical manufacturing plant is pictured at 50 ImClone Drive in Branchburg, New Jersey, March 5, 2021. Picture taken March 5, 2021. REUTERS/Mike Segar/File Photo -Eli Lilly and Co will buy Point Biopharma Global for $1.4 billion, the companies said on Tuesday, gaining access to experimental therapies that enable precise targeting of cancer.
The company's acquisitions this year include the $2.4 billion buyout of Dice Therapeutics and the $1.93 billion purchase of privately held Versanis.
Singapore Latest News, Singapore Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Lilly to Buy Point Biopharma. Cancer-Treatment Stock Surges 84%.Drug maker Eli Lilly agreed to acquire radiopharmaceutical company Point Biopharma Global for $12.50 a share.
Read more »
Point Biopharma, ALX Oncology surge premarket; McCormick, Airbnb falls By Investing.comPoint Biopharma, ALX Oncology surge premarket; McCormick, Airbnb falls
Read more »
Eli Lilly Acquiring Cancer Therapy Developer For $1.4 Billion—A Nearly 90% PremiumAmerican pharmaceutical company Eli Lilly plans to acquire cancer therapy firm Point Biopharma Global, the companies announced Tuesday, an expansion that comes as manu...
Read more »
Stocks making the biggest moves premarket: Warby Parker, HP, Point Biopharma and moreThese are the stocks posting the largest moves in premarket trading.
Read more »
Eli Lilly gets FDA complete response letter for skin treatment after inspection of third-party facilityEli Lilly & Co. said Monday the U.S. Food and Drug Administration has issued a complete response letter for its lebrikizumab, a treatment for...
Read more »
Eli Lilly Gets FDA Letter About Eczema Drug ConcernsThe pharmaceutical company says the letter cited no worries about the safety of its lebrikizumab skin treatment.
Read more »